Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues

Sunami, Kuniko
Furuta, Koh
Tsuta, Koji
Sasada, Shinji
Izumo, Takehiro
Nakaoku, Takashi
Shimada, Yoko
Saito, Motonobu
Nokihara, Hiroshi
Watanabe, Shun-ichi
Ohe, Yuichiro
Kohno, Takashi

Open PDF

Open link

Publication date

February 2016

DOI

10.1016/j.jtho.2015.10.005

Publisher

International Association for the Study of Lung Cancer. Published by Elsevier Inc.

ISSN

1556-0864

Citation count (estimate)

Abstract

AbstractIntroductionFusions of the anaplastic lymphoma receptor tyrosine kinase gene (ALK), ret proto-oncogene (RET), ROS proto-oncogene 1, receptor tyrosine kinase gene (ROS1), B-Raf proto-oncogene, serine/threonine kinase gene (BRAF), and neuregulin 1 gene (NRG1) and intronic MMNG HOS Transforming gene (MET) mutations are druggable oncogene alterations in lung adenocarcinoma that cause expression of aberrant transcripts. Because these aberrant transcripts are both infrequent (incidence <5%) and mutually exclusive, multiplex assays are required to detect them in tumor samples.MethodsAberrant transcripts of the six aforementioned oncogenes (36 transcripts in total) were examined in a molecular counting (MC) assay, which counts RNA molecules...